Swiss Franc eyes first weekly gain in five weeks as weak NFP delays Fed hikes
USD/CHF heads for its first weekly loss in five weeks as weaker-than-expected US Nonfarm Payrolls (NFP) data released on Thursday weighed on the US Dollar (USD). The pair rebounds on Friday as the Greenback stabilizes, with traders reassessing the Federal Reserve's (Fed) interest rate outlook.
At the time of writing, USD/CHF is trading virtually unchanged around 0.8034 after touching an intraday low of 0.8010. The US Dollar Index (DXY), which tracks the Greenback's value against a basket of six major currencies, is trading around 100.84, recovering from an intraday low of 100.61.
The lack of follow-through selling in the US Dollar (USD) after the weak NFP print suggests the data merely delayed expectations of Federal Reserve (Fed) interest rate hikes.
Traders continue to expect monetary policy to remain restrictive as inflation remains above the central bank's 2% target after accelerating in recent months, driven by higher Oil prices.
According to the CME FedWatch Tool, traders are pricing in a 53% probability of a rate hike at the September meeting, down from 63% before the NFP release, while the probability of a December rate hike remains elevated at 76%.
However, the June Consumer Price Index (CPI) report due later this month is likely to provide greater clarity on the Fed's interest rate path, with energy-driven inflation risks easing as Oil prices have retraced most of the gains triggered by the US-Iran war.
In the meantime, the US Dollar's pullback may remain shallow, limiting stronger gains in the Swiss Franc (CHF).
On the Swiss side, the low-inflation backdrop supports the view that the Swiss National Bank (SNB) will maintain its current policy stance, keeping interest rates at 0%. Meanwhile, the central bank continues to warn against excessive strength in the Swiss Franc and remains ready to intervene in the foreign exchange market if necessary.
Looking ahead to next week, traders will focus on the US ISM Services Purchasing Managers Index (PMI) data, followed by the minutes of the Fed's latest policy meeting. The Swiss economic calendar remains empty.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
As AI controversies escalate, hedge funds buy tech stocks at the fastest pace in 15 months
Hedge funds have recorded net purchases of US TMT stocks on 10 out of the past 11 trading days, rebuilding tech long positions at the fastest pace in 15 months. However, an AI policy storm has struck at the "worst possible time"—calls by AI giants to slow down development have been rejected, and regulatory uncertainty has directly hit Asian tech stocks such as Softbank. As the tech sector's bullish run coincides with Super Central Bank Week, the sector now faces a severe test.
Apple Pre-sale Tracker: iPhone 18 Pro Series Shows Weak Overseas Demand Signals, Duo Review Positive but Hardware Lags Behind
According to a survey by Jefferies, after the launch of the iPhone 18 Pro, delivery wait times in the four major markets—the US, UK, Germany, and Japan—have shortened by 5 to 11 days compared to last year, with no wait time in the US. Given stable production capacity, this is a clear sign of weak demand. Although the China and Hong Kong markets have performed better against the trend, there are still suspicions of speculative stockpiling. The new foldable Duo has been praised for its software experience, but its $2,000 price tag comes with a 254-gram body and dual-camera setup, leaving its hardware lagging significantly behind Android competitors. Jefferies maintains an "underperform" rating, with a target price implying a 21% downside from the current level.
SUI holds $0.71 support as analysts cite key buy signal, eyes on possible recovery
UBS Health Benefit Survey: Elevance Health (ELV.US) Leads, U.S. Employers Prepare for Rising Medical Costs
In the annual survey by UBS for employee benefits management institutions, Elevance Health (ELV.US) emerged as the highest-rated US health insurance company.

